Urothelial Cancer | Specialty

The OncLive Urology condition center page is a comprehensive resource for clinical news and expert insights on urologic cancers, including prostate cancer, bladder cancer, testicular cancer, penile cancer, and renal cell carcinoma. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.

Five Under 5: Top Oncology Videos for the Week of 7/13

July 20th 2025

The top 5 OncLive videos of the week cover insights in ovarian cancer, RCC, melanoma, non–small cell lung cancer, and non–muscle-invasive bladder cancer.

FDA Grants Priority Review to TAR-200 for BCG-Unresponsive High-Risk NMIBC

July 17th 2025

The FDA granted priority review to TAR-200 for BCG-unresponsive, high-risk NMIBC with CIS, with or without papillary tumors.

Five Under 5: Top Oncology Videos for the Week of 7/6

July 13th 2025

The top 5 OncLive videos of the week cover insights in ovarian cancer, RCC, melanoma, non–small cell lung cancer, and non–muscle-invasive bladder cancer.

Dr Hayne on the Implications of the ANZUP 1301 Trial of Mitomycin Plus BCG in NMIBC

July 9th 2025

Dickon Hayne, MD, FRCS, MBBS, discusses mitomycin in combination with BCG in patients with high-risk non–muscle-invasive bladder cancer.

Dr Powles on Implications of the CREST Study of Sasanlimab Plus BCG in BCG-Naive NMIBC

July 8th 2025

Thomas Powles, MD, MBBS, MRCP, discusses the implications of data from sasanlimab plus BCG in patients with BCG-naive, high-risk NMIBC.

Padeliporfin Vascular Targeted Photodynamic Therapy Safely Produces High Response Rates in Low-Grade Upper Tract Urothelial Cancer

July 8th 2025

Padeliporfin vascular targeted photodynamic therapy was highly active with a tolerable safety profile in low-grade upper tract urothelial cancer.

Nogapendekin Alfa Inbakicept Plus BCG Approved in UK for BCG-Unresponsive NMIBC With CIS

July 8th 2025

The combination of nogapendekin alfa inbakicept and BCG is now approved in the United Kingdom for the treatment of patients with NMIBC with CIS.

Dr Lotan on Guideline-Supported Treatment Decision-Making for NMIBC

July 7th 2025

Yair Lotan, MD, discusses guideline-supported treatment avenues for patients with BCG-unresponsive NMIBC.

The OncFive: Top Oncology Articles for the Week of 6/29

July 5th 2025

The FDA grants approval to sunvozertinib in NSCLC and linvoseltamab in myeloma and removes REMS requirements for approved CAR T-cell therapies.

OncLive’s FDA Approval Report: The Regulatory Rundown for June 2025

July 1st 2025

Here is your guide to all therapeutic options that were cleared by the FDA in June 2025 spanning tumor types.

Zelenectide Pevedotin Plus Pembrolizumab Is Safe and Active in Treatment-Naive, Cisplatin-Ineligible Advanced Urothelial Cancer

June 30th 2025

The combination of zelenectide pevedotin and pembrolizumab was safe and produced antitumor activity in cisplatin-ineligible urothelial cancer.

The OncFive: Top Oncology Updates for the Week of 6/8

June 14th 2025

The FDA has approved new options in head and neck cancer, lung cancer, and bladder cancer—and more from OncLive this week.

Dr Sonpavde on Nivolumab Plus Ipilimumab in Untreated Unresectable/Metastatic Urothelial Carcinoma

June 12th 2025

Guru P. Sonpavde, MD, discusses nivolumab plus ipilimumab in treatment-naive unresectable or metastatic urothelial carcinoma.

Dr Hayne on Mitomycin/BCG as an Alternative to BCG Alone in Non–Muscle-Invasive Bladder Cancer

June 12th 2025

Dickon Hayne, MD, FRCS, MBBS, discusses the use of mitomycin plus BCG as a potential alternative to BCG alone in non–muscle-invasive bladder cancer.

Dr Huang on the FDA Approval of Mitomycin Intravesical Solution for Recurrent, Low-Grade, Intermediate-Risk NMIBC

June 12th 2025

William C. Huang, MD, details the FDA approval of intravesical mitomycin for recurrent, low-grade, intermediate-risk non–muscle invasive bladder cancer.

FDA Approves Intravesical Mitomycin for Recurrent, Low-Grade, Intermediate-Risk NMIBC

June 12th 2025

The FDA approved mitomycin intravesical solution for recurrnet, low-grade, intermediate-risk non–muscle-invasive bladder cancer.

EV-302 Regimen Shows Sustained Efficacy Vs Chemo Across Key Subgroups of Urothelial Cancer

June 10th 2025

First-line enfortumab vedotin plus pembrolizumab continued to demonstrate efficacy across subgroups of locally advanced or metastatic urothelial carcinoma.

ABLE-32 Looks to Expand the Use of Nadofaragene Firadenovec Into Intermediate-Risk NMIBC

June 10th 2025

A deep dive into the phase 3b ABLE-32 trial reveals the need for more treatments for patients with intermediate-risk NMIBC.

UGN-102 Elicits Nearly 80% CR Rate in Recurrent Low-Grade NMIBC

June 9th 2025

UGN-102 showed strong responses in patients with recurrent, intermediate-risk, low-grade non–muscle-invasive bladder cancer, per the phase 3 ENVISION trial.

Dr Schmidt on the Role of Minimally Invasive and Robotic Modalities in Bladder Cancer

June 9th 2025

Bogdana Schmidt, MD, MPH, discusses the role of minimally invasive and robotic strategies for the treatment of patients with bladder cancer.